ASPS, accounting for less than 1% of all soft tissue sarcomas and occurring preferentially in young adults, is characterized by the t(X;17)(p11;q25) translocation, which codes for a chimeric ASPSCR1-TFE3 transcription factor, and is known for its sensitivity to TKI therapy with a response rate of approximately 30% [19]. This evidence concerns the gene TFE3 and soft tissue sarcoma.